Contact
Please use this form to send email to PR contact of this press release:
Karolinska Development portfolio company Aprea Therapeutics enrolls first patients in Phase II trial of APR-246 in ovarian cancer
TO:
Please use this form to send email to PR contact of this press release:
Karolinska Development portfolio company Aprea Therapeutics enrolls first patients in Phase II trial of APR-246 in ovarian cancer
TO: